SILVER SPRING
Vabysmo label updated for macular edema treatment extension
- Sponsor
- Genentech $RHHBY
- Drug
- Vabysmo · faricimab-svoa
- Indication
- macular edema following retinal vein occlusion
FDA approved an updated label for Vabysmo (faricimab-svoa) to extend treatment duration for macular edema following retinal vein occlusion beyond six months.
What this means
Vabysmo is an eye injection that treats swelling in the retina by blocking two proteins that cause leaky blood vessels. The FDA updated its label to allow longer intervals between doses for patients with macular edema after retinal vein occlusion, potentially reducing the number of injections needed. This could mean fewer doctor visits for patients while maintaining vision protection.